Evidence map›Paper›PMID 38357203›Full record

ArticleFrontiers in oncology2024

Case report: A lung squamous cell carcinoma patient with a rare

Zhen-Feng Zhu, Xu-Xia Bao, Hong-Yan Shi, Xi-Xi Gu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zhen-Feng ZhuDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Xu-Xia BaoDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Hong-Yan ShiMedical Department, Genecast Biotechnology Co., Ltd, Wuxi, China.
Xi-Xi GuDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhongshan Hospital · CNGenecast (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer treatment has transitioned fully into the era of immunotherapy, yielding substantial improvements in survival rate for patients with advanced non-small cell lung cancer (NSCLC). In this report, we present a case featuring a rare epidermal growth factor receptor (

Indexed as

afatinibanti-PD1 therapyEGFR G719X mutationinflammatory microenvironmentlung squamous cell carcinoma

Identifiers

PMID38357203
PMCPMC10864480
OpenAlexW4391398007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.